

REMARKS

Claims 7 and 9-13 are all the claims pending in the application. Upon entry of this amendment claims 7 and 9-13 will be cancelled and new claims 14-21 will be pending.

Support for the new claims may be found throughout the specification and the claims as originally filed. For example, a method of both inhibiting proliferation of myeloma cells and suppressing bone resorption using 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-bisphosphonic acid may be found at page 6, first full paragraph, page 10, first full paragraph, etc.

Pharmaceutical carriers are discussed at page 11, last paragraph. Oral dosages of the compound are discussed at page 12, first full paragraph. Dosage amounts of the compound are discussed at page 14, first full paragraph.

No new matter has been added. Entry of the amendment is earnestly solicited.

COMMENTS ON THE PRIOR ART

Applicants respectfully assert that none of the prior art cited by the Examiner in the previous Office Actions in this application anticipates or makes obvious claims to a bisphosphonate compound that has the ability to both inhibit proliferation of myeloma cells and suppress bone resorption, or that has the ability to inhibit proliferation of myeloma cells.


Accordingly, reconsideration and allowance of this application are now believed to be in order, and such actions are hereby solicited. If any points remain in issue which the Examiner feels may be best resolved through a personal or telephone interview, the Examiner is kindly requested to contact the undersigned at the telephone number listed below.

AMENDMENT
U.S. APPLN. NO. 09/869,122

Q64929

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,



Drew Hissong
Registration No. 44,765

SUGHRUE MION, PLLC
2100 Pennsylvania Avenue, N.W.
Washington, D.C. 20037-3213
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

Date: September 26, 2002

AMENDMENT
U.S. APPLN. NO. 09/869,122

Q64929

APPENDIX
VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

Claims 7 and 9-13 are canceled.

Claims 14-21 are added as new claims.